91
91
Nov 6, 2013
11/13
by
CNBC
tv
eye 91
favorite 0
quote 0
lots of drugs but only one fda regulated quality standard. we think that's what the new law may accomplish and we're looking forward to that. >> okay. but we have seen instances where you break open the vial, where there's been horrible -- there's been deaths. >> well, there's been deaths when people have injected drugs that have compounded. there has been blindness from drugs injected in the eye. this is why we need one quality standard. we need the fda to regulate this and that's what i think the new compounding legislation, if it gets passed, will actually do, and it'll make things safer. >> now, just circle back, it's pertinent now. the diabetic, you're saying that's ready. that's one of the things -- you're saying they're just waiting. you're ready to go the moment that thing -- >> we are ready to go but we still have to go through the approval process. we've submitted -- >> what are those people taking right now? >> they're using lucentis, it's been approved. it ahead of us. there's some opportunity out there for people to get treated.
lots of drugs but only one fda regulated quality standard. we think that's what the new law may accomplish and we're looking forward to that. >> okay. but we have seen instances where you break open the vial, where there's been horrible -- there's been deaths. >> well, there's been deaths when people have injected drugs that have compounded. there has been blindness from drugs injected in the eye. this is why we need one quality standard. we need the fda to regulate this and that's...
195
195
Nov 7, 2013
11/13
by
CNBC
tv
eye 195
favorite 0
quote 0
now the fda saying it's not safe. and it could be an open question now how long it's going to take to get it all out of the u.s. food supply. but tyler, they say the industry has already gone to huge lengths to get transfats out of the food supply. this may not be a major disruption for a lot of people who saw this coming. >> eamon javers reporting. >>> there's been a lot of focus on tech ipos. of course, twitter today, facebook, linkedin, yelp. but there are a lot of nontech companies that have a big pop on days they went public. dominic has some details. sboo interesti >> interesting names, names we all know. follow me because visa, the huge credit card payments provider, they went public and they shot up huge. they were up 28% back in 2008 when they went public. that's one big name. then all of a sudden there's u.p.s., a huge cargo carrier, up 37% back when they went public in 1999. on the other side of things, the nyse is in focus. i.c.e., the intercontinental exchange, it soared 50% in its debut back in 2005. and
now the fda saying it's not safe. and it could be an open question now how long it's going to take to get it all out of the u.s. food supply. but tyler, they say the industry has already gone to huge lengths to get transfats out of the food supply. this may not be a major disruption for a lot of people who saw this coming. >> eamon javers reporting. >>> there's been a lot of focus on tech ipos. of course, twitter today, facebook, linkedin, yelp. but there are a lot of nontech...
76
76
Nov 7, 2013
11/13
by
CNBC
tv
eye 76
favorite 0
quote 0
the fda now making it official. and there's some question here about exactly how long it will take to do this entirely, but it's definitely here in process here in washington. >> thanks for the update. >>> next, jcp just did something it's not done in two years. could this ship final loy ly be turning around? >>> and shares of one tech partying like it is 1999. we'll tell you who it is and have a bull debate over it when "street signs" returns. [ bagpipes and drums playing over ] [ music transitions to rock ] make it happen with the all-new fidelity active trader pro. it's one more innovative reason serious investors are choosing fidelity. get 200 free trades when you open an account. shhhh! i have a cold with this annoying runny nose. [ sniffles ] i better take something. [ male announcer ] dayquil cold and flu doesn't treat that. it doesn't? [ male announcer ] alka-seltzer plus fights your worst cold symptoms plus has a fast-acting antihistamine. oh what a relief it is! plus has a fast-acting antihistamine. so all
the fda now making it official. and there's some question here about exactly how long it will take to do this entirely, but it's definitely here in process here in washington. >> thanks for the update. >>> next, jcp just did something it's not done in two years. could this ship final loy ly be turning around? >>> and shares of one tech partying like it is 1999. we'll tell you who it is and have a bull debate over it when "street signs" returns. [ bagpipes and...
131
131
Nov 5, 2013
11/13
by
CNBC
tv
eye 131
favorite 0
quote 0
and we've announced today we've filed with the fda to ask for approval for that drug. and we could be on the market as early as next year some time. >> i think this is huge. the doctors i deal with on this particular issue adon't know. they're deathly afraid something bad's going to happen. they have nothing for these people. this could be it. >> well, this is a great rescue medication. >> right. that's what i'm talking about. something happens, there's people -- i just don't think people realize how big it is. >> it -- we think it's a very important indication. >> with the time left, i -- we have regeneron on later, i remember the initial regeneron, spinal cord injuries, everybody cares. anything within five years possible here? >> i founded the company based on my interest in spinal cord injury. we know how awful it is. we have a really exciting medication. we just started a clinical trial in people with acute spinal cord injuries. and in preclinical studies, it showed a potential for rescuing spinal cord tissue so they preserve more function later. now, this trial's
and we've announced today we've filed with the fda to ask for approval for that drug. and we could be on the market as early as next year some time. >> i think this is huge. the doctors i deal with on this particular issue adon't know. they're deathly afraid something bad's going to happen. they have nothing for these people. this could be it. >> well, this is a great rescue medication. >> right. that's what i'm talking about. something happens, there's people -- i just don't...
76
76
Nov 11, 2013
11/13
by
CNBC
tv
eye 76
favorite 0
quote 0
where was the fda, you know, as this company was growing like gang busters? that's the big issue. >> okay. herb, you've got a glut ten free stock play for us. you have mentioned it before on "street signs." i understand there is more you would like to give us today? >> i have a piece on this on the street.com today. bolder brands reported earnings and a little miss in terms of what people were expecting but the real issue, when i go through this, i look what the analysts are saying, which is generally positive, the way i read it and they were togging on there about competition from a group which has a number of big brands in the united states. they have a new brand called good-bye gluten and the company's ceoer boulder brands ceo steven hughs was we're not seeing an impact from them. when you start getting this into the mainstream and you start getting competition, that creates price competition and that's what you have to look at going forward here. and you also have to look the at the bigger issue with gluten free. >> you think it's a fad? you think gluten
where was the fda, you know, as this company was growing like gang busters? that's the big issue. >> okay. herb, you've got a glut ten free stock play for us. you have mentioned it before on "street signs." i understand there is more you would like to give us today? >> i have a piece on this on the street.com today. bolder brands reported earnings and a little miss in terms of what people were expecting but the real issue, when i go through this, i look what the analysts...
90
90
Nov 5, 2013
11/13
by
CNBC
tv
eye 90
favorite 0
quote 0
they may get fda approval in february. should i hold? >> yes, i want you to hold because this is j & j's partner in this drug and j & j gets 50% and i think they're very excited about it. a little disappointed about j & j today. my charitable trust owns some. let's go to bill in new york, bill? >> caller: hey, jim, navios maritime partners. >> i like the fact that the baltic dry freight index is going up, that makes me like that stock. let's go to elise in maryland. elise? >> caller: hi, jim, you're my rock star stock star. >> i wish i were that good, but thank you. >> caller: you're quite welcome. looking at the negative action with acadia today, it appears no one needs it. can you give me insight? what's up with that? >> that's a good question. that's a very good question because, you know, i felt the parkinson's progress that they made was okay. let me make some calls. i think that's an okay stock. let's go to patrick in kentucky. patrick? >> caller: hey, a big kentucky wildcat boo-yah to ya. >> nice, love the wildcats. what's going o
they may get fda approval in february. should i hold? >> yes, i want you to hold because this is j & j's partner in this drug and j & j gets 50% and i think they're very excited about it. a little disappointed about j & j today. my charitable trust owns some. let's go to bill in new york, bill? >> caller: hey, jim, navios maritime partners. >> i like the fact that the baltic dry freight index is going up, that makes me like that stock. let's go to elise in...
330
330
Nov 6, 2013
11/13
by
CNBC
tv
eye 330
favorite 0
quote 2
did you really submit a 443,000 page document to -- >> that's what the fda submission -- >> what the heck is in that? >> a lot of things, but -- >> who reads -- does somebody read that? come on, they're skimmers down there. >> think of the pressure the fda is under because the patients should be read and fda has to render an opinion within 12 months. >> that's not possible. >> there's a lot of work. but from that -- we're very pleased because we submitted the largest clinical program on hypopyrothyroidism ever. >> for either of the drugs, we have to be careful because johnson & johnson is out with a drug, but i was blown away with how bad what happened to johnson & johnson. >> yes, rightfully so. >> very rightfully so, right? >> yeah. so gatix is indicated for those dependent on the support, and with expanding the drug to the pediatric population. >> right. that's important because that does bring in more people. >> but also, it's important baupz -- because some of the kids die in the absence of the treatment like gatix. >> i think some people at home are thinking why didn't dr. nade
did you really submit a 443,000 page document to -- >> that's what the fda submission -- >> what the heck is in that? >> a lot of things, but -- >> who reads -- does somebody read that? come on, they're skimmers down there. >> think of the pressure the fda is under because the patients should be read and fda has to render an opinion within 12 months. >> that's not possible. >> there's a lot of work. but from that -- we're very pleased because we...
126
126
Nov 18, 2013
11/13
by
CNBC
tv
eye 126
favorite 0
quote 0
but the fda is apparently going to give special permission to the school to administer it following a meningitis outbreak there. so should, seema, the school give out a foreign vaccine, the wrinkle here is that the traditional vaccine doesn't protect against the particular strain at princeton? >> right. some of the health care experts i spoke to say that the european approval process is rigorous for safety so this might be a good option, actually, for the students. >> why, sue, are we so far behind on something like this? in other words -- i don't know whether we're so far behind but we vice president approved it and it is approved apparently in europe and australia? >> yes. it has been approved in australia. it's widely used in europe. you know, i don't know that we are, quote, so far behind. however, there has been some finger-pointing at the administration and fda that perhaps they aren't as efficient as they could be at approving vaccines that show efficacy for certain ailments and i think they should allow them to give it to students at princeton because meningitis is such a dang
but the fda is apparently going to give special permission to the school to administer it following a meningitis outbreak there. so should, seema, the school give out a foreign vaccine, the wrinkle here is that the traditional vaccine doesn't protect against the particular strain at princeton? >> right. some of the health care experts i spoke to say that the european approval process is rigorous for safety so this might be a good option, actually, for the students. >> why, sue, are...
289
289
Nov 11, 2013
11/13
by
CNBC
tv
eye 289
favorite 0
quote 1
they're at mercy of fda. the seemingly disappointing guidance that caused the stock to plummet in trading. why do people do this? priceline is renowned for giving guidance. over the last seven quart rs, the company has beaten the forecast 876 basis points. forecast don't count. price line now has the new ceo jeffrey boyd. miracle worker, steps back from the ceo job but remains chairman. darren houston takes over january 1st. he's the guy behind booking.com. that's the priceline crown jewel. here's the bottom line. don't be freaked out by the price tag. this is incredibly well run stock down right cheap on the growth basis. you can play with the common stock. the best way is most conservative, deep in the money call options. dawn in california. >> caller: first of all, thank you for taking me call and the education you give to all of us. >> thank you dawn. doing my best here. >> caller: hey my question is about alliance data systems. i think they're a good company because they're a product of the futu future.
they're at mercy of fda. the seemingly disappointing guidance that caused the stock to plummet in trading. why do people do this? priceline is renowned for giving guidance. over the last seven quart rs, the company has beaten the forecast 876 basis points. forecast don't count. price line now has the new ceo jeffrey boyd. miracle worker, steps back from the ceo job but remains chairman. darren houston takes over january 1st. he's the guy behind booking.com. that's the priceline crown jewel....
234
234
Nov 12, 2013
11/13
by
CNBC
tv
eye 234
favorite 0
quote 0
sarepta is losing two-thirds of value after fda raised concerns about the ms drug calling application for sales premature. vanda pharma doubled after fda recommended approval of sleep disorder drug for blind saying it's safe and effective. fedex moving higher after dan lobe spoke to cnbc saying his fund was long fedex chairs. he met with ceo of fedex and doesn't want fed smith replaced. some movers, back over to you guys. >> thank you very much. let's take a break, shall we? coming back. we've got about 50 minutes left in the trading session here. the dow off the lows. we were down about 60 at the low of the session right after dennis lockhart spoke today. down 21 points right now. >> the deal is closing. enter continental exchange's acquisition of the nyse set to close tomorrow. up next, i.c.e. chairman jeff sprecher will lay out his views. first on cnbc interview. what did he mean recently when he said the markets are stacked against the little guy? don't miss that interview coming next. >> later -- is tesla considering recall of model s calls to prevent more battery fires from brea
sarepta is losing two-thirds of value after fda raised concerns about the ms drug calling application for sales premature. vanda pharma doubled after fda recommended approval of sleep disorder drug for blind saying it's safe and effective. fedex moving higher after dan lobe spoke to cnbc saying his fund was long fedex chairs. he met with ceo of fedex and doesn't want fed smith replaced. some movers, back over to you guys. >> thank you very much. let's take a break, shall we? coming back....
265
265
Nov 12, 2013
11/13
by
CNBC
tv
eye 265
favorite 0
quote 2
after the fda calls its drug application premature. >> big move. thank you, dom. straight ahead, a live interview with dan lowe. this is where you'll see him. the "new york times" deal book conference. he's expected to begin at any moment. when we come back, we'll bring his comments to you live. stay with us. ♪ like they helped millions of others. by listening. planning. working one on one. that's what ameriprise financial does. that's what they can do with you. that's how ameriprise puts more within reach. ♪ >>> welcome back to "squawk on the street." that's dan loeb backstage. a nice little look behind the scenes of what is truly an amazing conference. i don't know if you've seen the guest list, barry diller, senator carl levin, we're about to hear from dan loeb and later on a view from private equity, david reubenstein, david bonderman. the list goes on and on. >> and i think citadel's ken griffin, elon musk closing bell as well. >> elon musk 4:00 to 4:20, talking about tesla on a very busy week. no one can deliver the goods the way sorkin can. here's andre
after the fda calls its drug application premature. >> big move. thank you, dom. straight ahead, a live interview with dan lowe. this is where you'll see him. the "new york times" deal book conference. he's expected to begin at any moment. when we come back, we'll bring his comments to you live. stay with us. ♪ like they helped millions of others. by listening. planning. working one on one. that's what ameriprise financial does. that's what they can do with you. that's how...
234
234
Nov 23, 2013
11/13
by
CNBC
tv
eye 234
favorite 0
quote 1
cholesterol, i think this could spur a huge 2014 if the company can get that accelerated approval from the fda. remember, from bio gen today, expected approvals can give big bumps in these stocks. the four horsemen from the big apocalypse had been wandering in the wilderness. that stay looks to be over. i would buy all four even after these runs as these stocks are going to be anointed as go-to names for the rest of 2013. i need to speak to brian in washington. brian. >> caller: booya, cramer. >> wow, man, you are a player. you're playing. what's up. >> caller: hey, cramer, i would like to wish you of your team and pros on "mad money" the best of holidays. happy holidays to you guys. >> well, everyone's coming to my house for thanksgiving. not. >> caller: that's great. >> unlikely. >> caller: jim. >> yeah. >> caller: the rest of the country we have some great companies here in the northwest. i'm looking at seattle genetics. >> oh, man, i like that stock. we had on last night terrific. i absolutely think that's another stock that could rally into year end. that's a great, great call. and thank
cholesterol, i think this could spur a huge 2014 if the company can get that accelerated approval from the fda. remember, from bio gen today, expected approvals can give big bumps in these stocks. the four horsemen from the big apocalypse had been wandering in the wilderness. that stay looks to be over. i would buy all four even after these runs as these stocks are going to be anointed as go-to names for the rest of 2013. i need to speak to brian in washington. brian. >> caller: booya,...
93
93
Nov 11, 2013
11/13
by
CNBC
tv
eye 93
favorite 0
quote 0
investors are dealing with concerns resulting from a number of adverse event reports collected by the fda involving systems made by intuitive surgical. now this is not to say that there's any direct link between negative reports from these medical device makers an the company's products but it's still a potential worrying point for investors. stay tuned to "street signs" this afternoon where cnbc contributor herb greenberg will talk about this story. herb was one of the first ones out there to flag some of these concerns with medical robotics. we'll be tuning in for sure on that one. >> thanks so much. steve weiss? >> here's a story, missed a couple quarters, we saw the stock really took some gas. the question has always been, what's saturation for million dollar da vinci machines with health care trying to cut back. for me i would rather wait to see if they're on level footing before i step into it even though the multiples come down quite a bit. so do the earnings. >> goldman defending the stock. not so fast michael murphy, traders are quick but not always right. >> again? >> mike made
investors are dealing with concerns resulting from a number of adverse event reports collected by the fda involving systems made by intuitive surgical. now this is not to say that there's any direct link between negative reports from these medical device makers an the company's products but it's still a potential worrying point for investors. stay tuned to "street signs" this afternoon where cnbc contributor herb greenberg will talk about this story. herb was one of the first ones out...
76
76
Nov 22, 2013
11/13
by
CNBC
tv
eye 76
favorite 0
quote 0
more regulation of the fda, more creation of life science companies? we've had a real boom in ipos. >> yeah, what we're levered to is really the industry and this new movement, this industry cloud movement. as we get more and more life sciences customers using our software, our software gets better and better, and we start to generate unique data about the industry that we can sell back to the industry. so we're -- the thing to know about veeva or industry cloud in general, is it's actually in the very, very early days. it's somewhat a little bit less predictable and quite exciting. >> well, one of the things that i've discovered about legacy systems, they're a bit pernicious. they're deep down in codes for that company. it's expensive to pull out. when a deal is over for the legacy, is that when you do best? because you can't really rip out these legacy systems. >> well, we actually do replace them. but you're right, it's not easy. there has to be a need to do it. there has to be a major need. usually might come from the top in the organization where
more regulation of the fda, more creation of life science companies? we've had a real boom in ipos. >> yeah, what we're levered to is really the industry and this new movement, this industry cloud movement. as we get more and more life sciences customers using our software, our software gets better and better, and we start to generate unique data about the industry that we can sell back to the industry. so we're -- the thing to know about veeva or industry cloud in general, is it's...
197
197
Nov 12, 2013
11/13
by
CNBC
tv
eye 197
favorite 0
quote 0
surging in heavy trading after an fda pam said its sleep disorder drug for the blind is safe and effective and warns approval. keep in mind the market cap is around $335 million so on the smaller end but still one stock to pay attention to, back over to you. >> dom, thank you. there is a big power summit in new york. ceos and many of wall street's top investors sounding off on the economy, the markets and a whole lot more at new york's times deal book conference. cnbc is the exclusive broadcaster of that event. kate kelly is there live with highlights of fascinating conversations. kate? >> thanks so much, sue. i would say that within the last hour or so, things have taken a decidedly more bearish tone in terms of the global economy, especially leading off with blackrock ceo lawrence fink. fink talked about a number of issues, among other things wants the fed to start tapering as soon as december and predicted a significant leg down in the coming months and emerging markets, 12 to 15%. he expressed concerns as well about what's going on in various economies around europe. let's take a quick
surging in heavy trading after an fda pam said its sleep disorder drug for the blind is safe and effective and warns approval. keep in mind the market cap is around $335 million so on the smaller end but still one stock to pay attention to, back over to you. >> dom, thank you. there is a big power summit in new york. ceos and many of wall street's top investors sounding off on the economy, the markets and a whole lot more at new york's times deal book conference. cnbc is the exclusive...
174
174
Nov 15, 2013
11/13
by
CNBC
tv
eye 174
favorite 0
quote 0
just today the fda -- or the epa pulls back on ethanol mandates. what does exxon do? it popped. it's up 2% today. warren buffett has done it again. >> yeah. >> good for him. >> by the way, like you said, in is probably done during the debt ceiling. already wea've seen a big move n some of those stocks since then. i think what you said is really interesting. i'd like to get your thought on that, carol. the fact that larry is just back from keynoting this hedge fund conference and he's hearing hedge funds are going all in right now, particularly those playing catch-up, are we going to see this kind of catch-up and melt-up till year end and into 2014? does that get you concerned in any way that hedge funds, some of these guys, are actually alienating their usual way of investing and going all in because they miss so much of it? >> right. well, i think hedge funds haven't been hedge funds and not been hedging for a long time, maria. it is, to me, sort of a neon sign. while i do think the market will continue to go up, particularly with what we're hearing out of the fed for a little
just today the fda -- or the epa pulls back on ethanol mandates. what does exxon do? it popped. it's up 2% today. warren buffett has done it again. >> yeah. >> good for him. >> by the way, like you said, in is probably done during the debt ceiling. already wea've seen a big move n some of those stocks since then. i think what you said is really interesting. i'd like to get your thought on that, carol. the fact that larry is just back from keynoting this hedge fund conference...
33
33
Nov 22, 2013
11/13
by
CNBC
tv
eye 33
favorite 0
quote 0
the back story, the stock fell 44% back on october 31st after the fda here in the u.s. halted sales of that same drug because of treatment risks. shares of ariad around 380 right now but we're north of $20 the same time last year, so falling from grace but getting some of that back today. back over to you. >> certainly is. thank you very much. >>> well, happy holidays, everybody. because we found the cheapest gas in all america. sharon epperson has today's pump patrol. . >> the honeymoon may be over for low gas prices. today the national average is $3.24 a gallon. that's up 4 cents from a week ago. we're looking at refinery glitches in many parts of the country, namely the nation's largest refinery in port author, texas, as one of the causes in the uptick in gas prices. once those are worked out gas buddy says we should prices in a more comfortable range. the cheapest price for gasoline today is in bixby, oklahoma, at$.74 a gallon. prices are climbing nearly everywhere. yesterday six states had prices under $3 a gallon. today only two. oklahoma and kansas. and if prices
the back story, the stock fell 44% back on october 31st after the fda here in the u.s. halted sales of that same drug because of treatment risks. shares of ariad around 380 right now but we're north of $20 the same time last year, so falling from grace but getting some of that back today. back over to you. >> certainly is. thank you very much. >>> well, happy holidays, everybody. because we found the cheapest gas in all america. sharon epperson has today's pump patrol. . >>...
924
924
Nov 26, 2013
11/13
by
CNBC
tv
eye 924
favorite 0
quote 2
. >> fda, warren's google back, private start-up run by sergey brin's ex, due to lack of parnsy. you've done so many companies, what are they doing wrong if anything? >> i'm not sure here. this is my classic are the entrepreneurs doing the wrong thing, big government trying to jump in. a lot of people have used it and found value in it. i hope it gets sorted out. >> let's talk about what you see as the next big thing on the social media horizon, the corporate horizon. what are you looking at? >> things that are destructing real world technology layers like ubber are changing the world and smart everything. smart phones now, but what about a world of smart refrigerators. when your refrigerator reorders your soda, costco, walmart, they're in trouble and what about smart pants when your pants text you in the morning and tell you to lose some weight. >> i'm known around here as mr. smart pants. come on. >> i think these smart -- >> i'm ahead of the game. >> smartfication of our world will have a bigger impact and the people watching this. >> do we have the infrastructure, though, out
. >> fda, warren's google back, private start-up run by sergey brin's ex, due to lack of parnsy. you've done so many companies, what are they doing wrong if anything? >> i'm not sure here. this is my classic are the entrepreneurs doing the wrong thing, big government trying to jump in. a lot of people have used it and found value in it. i hope it gets sorted out. >> let's talk about what you see as the next big thing on the social media horizon, the corporate horizon. what are...
177
177
Nov 7, 2013
11/13
by
CNBC
tv
eye 177
favorite 0
quote 1
the fda declaring war on transfats. fanning the synthetic form of them. huge ramifications for food companies and food stocks. >>> twitter is so few hours ago, folks. we're going to tell you what companies the millennials will be investing in next, post-fwiter. >>> plus, making money off of weed, marijuana. we'll tell you who's rolling, get it, rolling in the profits and how. more "halftime" after this short break. americans take care of business. they always have. they always will. that's why you take charge of your future. your retirement. ♪ ameriprise advisors can help you like they've helped millions of others. listening, planning, working one on one. to help you retire your way... with confidence. that's what ameriprise financial does. that's what they can do with you. ameriprise financial. more within reach. >>> welcome back. another big story we're following across the pond over in europe where ecb president mario dragi surprised some folks by cutting interest rates a quarter point. that sent the euro falling which is exactly what our next guest
the fda declaring war on transfats. fanning the synthetic form of them. huge ramifications for food companies and food stocks. >>> twitter is so few hours ago, folks. we're going to tell you what companies the millennials will be investing in next, post-fwiter. >>> plus, making money off of weed, marijuana. we'll tell you who's rolling, get it, rolling in the profits and how. more "halftime" after this short break. americans take care of business. they always have....
221
221
Nov 12, 2013
11/13
by
CNBC
tv
eye 221
favorite 0
quote 0
the fda indicated that new data raised considerable doubt about the effectiveness measures used in a midstage trial. they thought it was going to be good. competitors had a set bang and there but for the grace of god the same thing happened to them. so it's a horrific -- not a huge company, market cap was almost 1.3 billion. you can take 54% off of shareholder -- off the market cap this morning. dish network -- if you watch the bottom ticker on the nasdaq that goes by every two seconds, dish network, third quarter profit of 68 cents a share, well above estimates of 43 cents and added 43,000 new subscribers during the quarter. >>> when we come back, catching fire, the latest film in the hunger games series, likely to be a big box office drawer. i max ceo rich goal fant will join us to talk about the other release and if it is really booming. be right back. is mine was earned orbiting the moon in 1971. afghanistan in 2009. on the u.s.s. saratoga in 1982. [ male announcer ] once it's earned, usaa auto insurance is often handed down from generation to generation because it offers a super
the fda indicated that new data raised considerable doubt about the effectiveness measures used in a midstage trial. they thought it was going to be good. competitors had a set bang and there but for the grace of god the same thing happened to them. so it's a horrific -- not a huge company, market cap was almost 1.3 billion. you can take 54% off of shareholder -- off the market cap this morning. dish network -- if you watch the bottom ticker on the nasdaq that goes by every two seconds, dish...
278
278
Nov 26, 2013
11/13
by
CNBC
tv
eye 278
favorite 0
quote 1
. >>> let's talk about the fda now warning 23 and me to halt sales of its genetic tests because they have not received regulatory clearance. the company 23 and me is backed by google and sells a $99 dna test that it says can provide information about a person's health risks. but regulators are worried that certainly false positive could and a false negative could failure to recognize a risk on a -- >> this is so ridiculous. >> number one, a false negative is better than no information. you're not going to get any information. you wouldn't do it, otherwise. so you're in the same position if you didn't do it n first place. and no one in their right minds is going to take a mail order test and go and get a mass tmas. now here we are with more oversight from the fda which has other things to focus on. >> andrew and i have both done this. >> we've both done it. >> i think it was like $200 when i did it, about 2 1/2 years ago. i never even looked up the results because i was doing it because i was interviewing ann wojicki who is the founder and ceo of the company. i wanted to do the whole
. >>> let's talk about the fda now warning 23 and me to halt sales of its genetic tests because they have not received regulatory clearance. the company 23 and me is backed by google and sells a $99 dna test that it says can provide information about a person's health risks. but regulators are worried that certainly false positive could and a false negative could failure to recognize a risk on a -- >> this is so ridiculous. >> number one, a false negative is better than no...
99
99
Nov 26, 2013
11/13
by
CNBC
tv
eye 99
favorite 0
quote 0
the fda has limited restrictions on the drug avan did i a saying it no longer includes heart risks. avandia was one of the world's top selling drugs, but sales began to fall in 2007 after researchers questioned link toes heart attacks. last week, penny's reported a wider third quarter loss in weak sales and margins, but uhlman said sales trends are improving. officials say the health cacarev website won't be working perfectly, but it will be able to handle 50,000 users at a time, which is the volume it was originally expected to ham when it launched. >>> still to come, chrysler is tapping the brakes on its ipo plan. find out what's hold onning up the automaker's plans to go public, next. ya know, with new fedex one rate you can fill that box and pay one flat rate. i didn't know the coal thing was real. it's very real... david rivera. rivera, david. [ male announcer ] fedex one rate. simple, flat rate shipping with the reliability of fedex. that's mine. ♪ that's mine. ♪ that's mine. ♪ come on, kyle. ♪ [ horn honks ] that's mine...kyle. [ male announcer ] revenge is best serve
the fda has limited restrictions on the drug avan did i a saying it no longer includes heart risks. avandia was one of the world's top selling drugs, but sales began to fall in 2007 after researchers questioned link toes heart attacks. last week, penny's reported a wider third quarter loss in weak sales and margins, but uhlman said sales trends are improving. officials say the health cacarev website won't be working perfectly, but it will be able to handle 50,000 users at a time, which is the...
219
219
Nov 7, 2013
11/13
by
CNBC
tv
eye 219
favorite 0
quote 0
lyrica is fda approved to treat diabetic nerve pain. lyrica is not for everyone. it may cause serious allergic reactions or suicidal thoughts or actions. tell your doctor right away if you have these, new, or worsening depression, or unusual changes in mood or behavior. or swelling, trouble breathing, rash, hives, blisters, changes in eyesight including blurry vision, muscle pain with fever, tired feeling, or skin sores from diabetes. common side effects are dizziness, sleepiness, weight gain and swelling of hands, legs and feet. don't drink alcohol while taking lyrica. don't drive or use machinery until you know how lyrica affects you. those who have had a drug or alcohol problem may be more likely to misuse lyrica. ask your doctor about lyrica today. it's specific treatment for diabetic nerve pain. to hear more of terry's story, visit lyrica.com. >>> welcome back to "squawk on the street." twitter is now officially a public company. opened for trade, zeroing in on almost $50 a share. a better than 90% pop at the open. went public, by the way, opening trade $45.1
lyrica is fda approved to treat diabetic nerve pain. lyrica is not for everyone. it may cause serious allergic reactions or suicidal thoughts or actions. tell your doctor right away if you have these, new, or worsening depression, or unusual changes in mood or behavior. or swelling, trouble breathing, rash, hives, blisters, changes in eyesight including blurry vision, muscle pain with fever, tired feeling, or skin sores from diabetes. common side effects are dizziness, sleepiness, weight gain...
234
234
Nov 25, 2013
11/13
by
CNBC
tv
eye 234
favorite 0
quote 0
in fact, so well it plans to resubmit it for fda approval within the next few weeks with an eye toward getting approval in june of 2013. we talked about a marketing partner with this drug. and they're hoping it does well. stock should be a big winner today. >>> we've got another story this morning that will make you anxious, or has me anxious. startling revelations from a congressional hearing last week on the vulnerability of healthcare.gov. joining us now to talk about is one of the cyber security experts that testified in washington. david kennedy. he's trusted sec ceo and known as a white hat hacker. how bad is it? from a security perspective, how bad is it? >> we started looking at the website when we noticed the performance issues happening on the site. and basically started poking and prodding a little bit looking at the security and found out it was pretty bad all around. and there were things we couldn't disclose because it was so critical in nature because of public information that we weren't able to show. >> when you say bad, what can you get at? what type of information co
in fact, so well it plans to resubmit it for fda approval within the next few weeks with an eye toward getting approval in june of 2013. we talked about a marketing partner with this drug. and they're hoping it does well. stock should be a big winner today. >>> we've got another story this morning that will make you anxious, or has me anxious. startling revelations from a congressional hearing last week on the vulnerability of healthcare.gov. joining us now to talk about is one of the...